Efficacy data of CoronaVac in Turkey – Authors’ response
- Tanriover MD
- DoÄanay HL
- Akova M
- et al.
The work to which they refer by Palacios and his colleagues
- Palacios R
- Batista AP
- CSN Albuquerque
- et al.
has not been published in a peer-reviewed journal; therefore, we cannot comment on the accuracy or comparability of its methods. Data from Indonesian trials has been published,
- Fadlyana E
- Rusmil K
- Tarigan R
- et al.
and although the primary method for this study was similar to ours, the COVID-19 case definition and methods used for active surveillance were different. Only 1,620 volunteers were included, but over a longer follow-up period (approximately 2.5 months) preventing a direct comparison of the primary endpoint.
- Fadlyana E
- Rusmil K
- Tarigan R
- et al.
Nonetheless, the efficacy of CoronaVac against serious illness in this study was 100% as there were no critical cases or deaths attributable to COVID-19, which is undoubtedly similar to our results.
- Tanriover MD
- DoÄanay HL
- Akova M
- et al.
indicating that the study would not allow commenting on long-term protection.
- Jara A
- Undurraga EA
- González C
- et al.
reported analysis of actual data from Chile, including approximately 10.2 million people vaccinated with CoronaVac. The adjusted vaccine efficacy among fully immunized individuals was 65.9% (95% CI 65.2 to 66.6) for the prevention of COVID-19 and 87.5% (86.7 to 88 , 2) for prevention. admission to hospital.
We do not declare any competing interests.
The references
- 1.
Efficacy and safety of an inactivated whole virion SARS-CoV-2 vaccine (CoronaVac): interim results from a double-blind, randomized, placebo-controlled phase 3 trial in Turkey.
Lancet. 2021; 398: 213-222
- 2.
Efficacy and safety of an inactivated COVID-19 vaccine in healthcare professionals in Brazil: the PROFISCOV study.
SSRN. 2021; ()
- 3.
Phase III, Observer-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine in Healthy Older Adults from 18 to 59 years old in Indonesia.
Vaccine. 2021; 39: 6520-6528
- 4.
Efficacy of an inactivated SARS-CoV-2 vaccine in Chile.
N Engl J Med. 2021; 385: 875-884
Item Info
Publication history
Posted: 20 November 2021
Identification
DOI: https://doi.org/10.1016/S0140-6736(21)02286-8
Copyright
© 2021 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirect
Comments are closed.